Initial Treatment for Male UTI

Introduction to Male UTI Treatment

The European Association of Urology recommends treating all UTIs in males as complicated infections requiring 14 days of antibiotic therapy, with trimethoprim-sulfamethoxazole (160/800 mg twice daily) as the first-line agent when fluoroquinolone resistance is <10% in the region, due to anatomical factors and the inability to exclude prostate involvement at initial presentation 1, 2, 3.
The microbial spectrum in male UTIs is broader than uncomplicated female cystitis, with higher rates of antimicrobial resistance including E. coli, Proteus species, Klebsiella species, Pseudomonas species, Serratia species, and Enterococcus species 1, 2, 3.

The American College of Physicians recommends trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days as the preferred first-line agent for stable patients without systemic symptoms 4.
Ciprofloxacin 500-750 mg twice daily for 14 days is an alternative if TMP-SMX resistance exceeds 10% locally or if the patient has allergies, according to the European Urology guidelines 2, 3.
Levofloxacin 750 mg once daily for 14 days provides convenient once-daily dosing with similar efficacy to ciprofloxacin, as recommended by the European Urology guidelines 2, 3.

The European Urology guidelines recommend initiating with intravenous ciprofloxacin 400 mg twice daily or levofloxacin 750 mg once daily as first-line parenteral therapy for patients with systemic symptoms, fever, or suspected pyelonephritis 1, 2.
Ceftriaxone 1-2 g once daily or cefepime 1-2 g twice daily are alternative parenteral options, particularly when fluoroquinolone resistance is suspected, according to the European Urology guidelines 1, 2.

The European Association of Urology recommends obtaining urine culture and susceptibility testing in all male patients to guide potential therapy adjustments, as resistance patterns are more variable than in female uncomplicated UTIs 3.
Assessing for urological abnormalities including obstruction, incomplete voiding, recent instrumentation, or catheterization is crucial, as recommended by the European Urology guidelines 1, 2, 3.

The European Urology guidelines recommend escalating to carbapenems (meropenem 1 g three times daily or imipenem-cilastatin 0.5 g three times daily) for definitive therapy if early culture results indicate ESBL-producing organisms or other multidrug-resistant pathogens 1, 2.
Novel beta-lactam combinations including ceftazidime-avibactam 2.5 g three times daily or meropenem-vaborbactam 2 g three times daily are reserved for confirmed resistant organisms, as recommended by the European Urology guidelines and the American College of Physicians 1, 2, 4.